Context: Somatostatin reduces LH, GH, and insulin, and somatostatin receptors are present at the ovarian level; somatostatin analogs are thus potential candidates for treatment of the polycystic ovary syndrome (PCOS).
T HE POLYCYSTIC OVARY syndrome (PCOS) is a com-
plex and heterogeneous disorder whose cardinal features are hyperandrogenism and chronic oligo-anovulation (1). However, most PCOS patients, particularly those with an abdominal obesity phenotype (2) , also present with insulin resistance, which is intimately related to the development and maintenance of the syndrome (2) . Hyperinsulinemia, the consequence of the insulin resistance state, is directly involved in determining an increase in androgen availability in peripheral target tissues by stimulating ovarian and adrenal steroidogenesis and decreasing hepatic SHBG synthesis (2) . Although elevated LH concentrations, due to increased pituitary sensitivity to GnRH stimulation, represent one of the alternative mechanisms responsible for increased ovarian steroidogenesis, insulin synergizes with LH at the ovarian level, thus favoring excess thecal cell androgen production (1, 2) . Moreover, insulin seems to increase the sensitivity of granulosa cells to FSH, and in this way, hyperinsulinemia may contribute to increase ovarian dimension and to favor the development of small antral follicles (3) .
Hyperinsulinemia is considered one of the main factors involved in the pathogenesis of anovulation and infertility in PCOS women (4) , as a consequence of an interaction with the IGF system (5). In particular, by suppressing hepatic and ovarian IGF-binding protein-1 (IGFBP-1) synthesis, insulin increases the bioavailability of the IGFs, therefore synergizing to stimulate ovarian steroidogenesis and to modulate ovarian follicle growth and apoptosis (5) . The increased IGF availability observed in PCOS, however, seems to be differently determined in obese and normal weight subjects (6) . In obese PCOS women, IGF-I alterations appear to be strictly related to the effects of hyperinsulinemia, whereas in normal weight PCOS women, they seem to be the consequence of increased pituitary secretion and relatively high circulating concentrations of GH (6) . Therefore, the insulin-GH-IGF system appears to play a crucial role in the pathophysiology of PCOS.
Somatostatin is an endogenous hypothalamic peptide with a short half-life that, besides blunting the LH response to GnRH (7) and decreasing GH pituitary secretion (8) , inhibits pancreatic insulin release (9) . In addition, the recent discovery of somatostatin receptors at the adrenal (10) and ovary (11) levels suggests that these two organs may be under direct control of somatostatin. Preliminary studies by Prelevic and colleagues (12) showed that 7-d administration of octreotide, a synthetic somatostatin analog with a half-life of 80 -110 min, improved pulsatile gonadotropin patterns, reduced androgen levels, and decreased fasting and glucosestimulated insulin concentrations in PCOS women. More recently, a few other prospective, noncontrolled, short-term studies using octreotide expanded these findings (13) (14) (15) (16) (17) (18) (19) (20) , showing that this compound not only reduced insulin, IGF-I, LH, and androgen levels (13) (14) (15) (16) (17) (18) (19) (20) , but also increased spontaneous (13) and stimulated ovulation (14, 20) in PCOS patients. Unfortunately, the daily multiple sc injections required by the short life of octreotide makes this procedure inappropriate for a long-term treatment.
With this background, we carried out this placebo-controlled study to evaluate the effect of prolonged therapy with a long-acting somatostatin analog formulation (octreotide-LAR), injected im every 28 d, in a selected group of anovulatory PCOS women with abdominal obesity. Octreotide-LAR consists of octreotide acetate encapsulated with a biodegradable polymer (21) . Its slow and constant drug release into the circulation makes it possible to improve patient compliance by avoiding repeated daily sc injections (21) . An additional advantage of this formulation is a decreased occurrence of side effects, such as gallstone formation (21) .
Subjects and Methods Subjects
Twenty consecutive overweight or obese women with PCOS attending the Division of Endocrinology, Department of Internal Medicine, S. Orsola-Malpighi Hospital of Bologna were invited to participate in the study. No additional women were screened, because all invited women consented to participate after clinical examination and baseline blood tests were performed, and diagnosis was made. Their body mass index (BMI) values were greater than 28 kg/m 2 , and the waist to hip ratios were greater than 0.80, consistent with an abdominal fat distribution phenotype (22) . The diagnosis of PCOS was made according to the presence of chronic anovulation [supported by luteal progesterone (P) measurement] (23), oligomenorrhea/amenorrhea, hirsutism (FerrimanGallwey score, Ն8) (24), or elevations in blood levels of total (T) and free (FAI) testosterone (25) , and polycystic ovarian morphology at ultrasound (1). None had Cushing's syndrome; late-onset congenital adrenal hyperplasia; hyperprolactinemia; thyroid dysfunction; diabetes; cardiovascular, renal, or liver disease; or gallstones. Moreover, no patient had taken any medication or significantly modified her body weight in the 3 months preceding the study, nor was any subject dieting.
Human chorionic gonadotropin was measured in each subject before the start of the study to exclude pregnancy. All women were also advised orally and in writing to use nonhormonal contraception throughout the study. The protocol was approved by the local ethics committee, and all women gave their informed and written consents to participate in the study.
Protocol study
At baseline, blood samples for hormonal and metabolic parameters were drawn between 0800 and 0830 h after overnight fasting, followed by an oral glucose tolerance test (OGTT; 75 g; Curvosio, Sclavo, Cinisello Balsamo, Italy). On the same day, an evaluation of anthropometric parameters (height, weight, and waist and hip circumferences), hirsutism, and acanthosis nigricans was performed. Hirsutism was estimated by the Ferriman-Gallwey score (24) , whereas acanthosis nigricans was classified according to scale described in Ref. 26 . A computerized tomography (CT) scan measurement of body fat distribution was also performed at the level of L4 -L5 to estimate total (TAT), visceral (VAT), and sc (SAT) adipose tissue areas (25) . On the following day, all women were placed on a hypocaloric diet, ranging from 1200 -1420 kcal/d, with 15% total proteins, 30% lipids, and 55% carbohydrates. All diets were prescribed by the same dietician, who calculated the dietary energy intake by subtracting 500 kcal from the usual individual energy intake. Habitual energy intake was calculated by means of the diet history method and a 3-d recall questionnaire. The women returned after 1 month for anthropometry and CT scan measurements. After this period and while continuing dietary treatment, PCOS women were scheduled to receive, in a random order and according to a single-blind design, octreotide-LAR (Novartis Farma S.p.A., Origgio-Varese, Italy; 10 mg; n ϭ 10) or placebo (saline solution; n ϭ 10), one im injection every 28 d for the following 6 months. The random allocation sequence to the two treatments was decided before the recruitment of the patients. Treatment with octreotide-LAR or placebo was preceded by 3 d of treatment with octreotide (Novartis Farma S.p.A.; 100 g, sc, twice a day) or an equal amount of saline solution to test the individual tolerability to the drug. One investigator (L.P.) generated the random allocation sequence and administered the drugs (active or placebo) at the out-patient clinic for the entire period of the study, whereas another investigator (A.G.), blinded to group assignment, enrolled and regularly checked all patients at monthly intervals during the study to evaluate the appearance of side effects and tolerance to the treatments. The compliance with diet was evaluated by the same dietician at each visit, according to a previously defined method providing quantitative information on daily energy intake and macronutrient composition of the diet performed during the previous month. Patients failing to comply with dietary prescription (Ͼ30% excess kcal intake) were excluded from the study. Patients were also directed to maintain their usual physical activity, which was checked monthly by the self-administered questionnaire proposed by Baecke et al. (27) . The frequency of menses during the study and in the 7 months previous to it were also evaluated and were expressed as menstrual status. At the end of the trial, a final examination was conducted by analyzing all measurements performed at baseline.
Finally, the occurrence of ovulation in each patient was monitored during both the first and the last menstrual cycle occurring during treatment with octreotide-LAR or placebo. Ovulation was assessed by performing pelvic ultrasound and by measuring serum levels of LH, FSH, estradiol (E 2 ), and P at 7, 14, 21, and 28 d after the start of menstrual bleeding. Ovulation was assumed to have occurred when a dominant follicle with a diameter higher than 12 mm or a corpus luteum was seen on pelvic ultrasound scanning, and P and E 2 concentrations were higher than 8 ng/ml and 100 pg/ml, respectively (23) .
During the treatment period, two women in the placebo group were excluded because of noncompliance with the diet, one in the first and the other in the third month of treatment. The cohort available for final statistical analysis, therefore, included 18 PCOS women, 10 treated with octreotide-LAR and eight given placebo. A schematic representation of the study design is shown in Fig. 1 .
Tolerance and side effects
To assess the tolerance and the appearance of side effects, a selfadministered questionnaire was given, and a blood sample was obtained at each monthly visit. The questionnaire evaluated the presence of gastrointestinal disturbances, such as abdominal pain, abdominal swelling, flatulence, diarrhea, nausea, and vomiting, and the appearance of pain, swelling, and blushing at the site of the im injection. Blood tests included liver enzymes, bilirubin, and complete blood count. A gallbladder ultrasound was also performed at the start and the end of the study to detect any gallstone formation.
Assays
Blood samples were centrifuged immediately, and serum was stored at Ϫ20 C; plasma was kept at Ϫ80 C until assayed. Plasma glucose levels were determined by the glucose oxidase method. Insulin, LH, FSH, T, dehydroepiandrosterone sulfate (DHEA-S), E 2 , P, androstenedione (A), 17-hydroxyprogesterone (17-OHP), 17-hydroxypregnenolone (17-OHPreg), cortisol, SHBG, IGFBP-1, IGFBP-2, IGFBP-3, and total plasma ghrelin were measured as previously described (28 -30) . GH was measured by the immunochemiluminescence assay, and IGF-I was determined by immunoradiometric assay. FAI was calculated as the ratio between total T and SHBG (31) . To investigate insulin sensitivity, the homeostasis model assessment (HOMA), the quantitative insulin-sensitivity check index (QUICKI), and the insulin sensitivity index during the OGTT [ISI(composite)] were calculated (32) (33) (34) .
The intraassay coefficients of variation in our laboratory were 3.0% for insulin, 4.8% for LH, 1.9% for FSH, 7.0% for T, 5.9% for DHEA-S, 5.6% for E 2 , 4.1% for P, 6.0% for A, 13% for 17-OHP, 8% for 17-OHPreg, 10% for cortisol, 6.5% for SHBG, 2.5% for IGFBP-1, 6% for IGFBP-2, 3.25% for IGFBP-3, 5.3% for ghrelin, 5% for GH, and 6% for IGF-I.
Statistical analysis
Results were reported as the mean Ϯ sd unless otherwise indicated. The responses of glucose and insulin to the OGTT were analyzed by calculating the area under the curve (AUC) by the trapezoidal method. A one-way ANOVA was applied to compare values between groups at baseline, whereas the repeated measure ANOVA was performed to estimate the within-and between-group modifications. The occurrence of ovulation and side effects and the tolerance to the treatments were analyzed by means of Fisher's exact test (baseline values between groups), the McNemar test (modifications within groups), and the hierarchical log-linear models (modifications between groups). Statistical analyses were performed by running the SPSS/PC ϩ (SPSS, Inc., Chicago, IL) software package (35) . Two-tailed P Ͻ 0.05 was used to define statistical significance.
Results

Compliance with treatments, tolerance, and side effects
All patients completing the study had excellent compliance with both dietary and pharmacological treatments, without any significant difference in energy intake or physical activity score between the two groups. Treatments were well tolerated by all of the women. In particular, none reported the appearance of vomiting or of pain, swelling, and blushing at the site of the im injection for the entire period of the study. Three women treated with octreotide reported slight abdominal pain and nausea once during the study compared with none of those receiving placebo (P ϭ 0.216 for abdominal pain and P ϭ 0.147 for nausea in the betweengroup analysis). Three octreotide-treated patients developed slight diarrhea and complained about flatulence at least once compared with one in the placebo-treated group, but no between-group differences were present (P ϭ 0.588 for both parameters). Moreover, three women in each group reported the appearance of moderate abdominal swelling once during the study (P ϭ 0.563 in the between-group analysis). None developed side effects, including gallstones.
Anthropometry and fat distribution
No significant difference in baseline parameters existed between the two groups ( Table 1) . Body weight, BMI, and TAT values decreased significantly and in a comparable manner from baseline to month 1 in the two groups, without any significant change in the other parameters. Octreotide-LAR-treated, but not placebo-treated, patients also significantly reduced body weight, BMI, waist circumference, and SAT values during the 6-month treatment. However, we found no significant difference in the changes in these parameters after each treatment between the two groups ( Table  1 ). In addition, no treatment had a significant effect on waist to hip ratio, TAT, VAT, or the VAT/SAT ratio (Table 1) .
Gonadotropins, steroid hormones, and SHBG
Steroid hormones and SHBG concentrations at baseline were comparable in the two groups. No treatment significantly modified serum levels of LH, FSH, FAI, 17-OHP, 17-OHPreg, P, DHEA-S, E 2 , SHBG, or cortisol. T and A levels significantly decreased in the octreotide-LAR-treated, but not in the placebo-treated, group (Table 2 ). There were no significant differences in the hormonal changes after each treatment between the two groups, although a trend toward greater reductions in T (P ϭ 0.061) and A (P ϭ 0.069) levels was observed in PCOS women treated with octreotide-LAR ( Table 2) . 
Glucose, insulin, and insulin resistance indices
Fasting and glucose-stimulated values of glucose and insulin (Fig. 2) and the insulin resistance indices (Fig. 3) at baseline were not different in the two groups. Fasting and 60-min stimulated glucose values increased with a borderline significance only in the octreotide-LAR group, whereas glucose values at 120 min from the glucose load significantly decreased only in the placebo group. However, no significant changes occurred in the glucose AUC in either group. Fasting insulin significantly decreased in both groups, but a greater reduction was observed in the octreotide-LAR group than in the placebo group (P ϭ 0.018). The 60-min glucose- stimulated insulin values significantly decreased only in the octreotide-LAR group, but no between-group differences were present (P ϭ 0.332). The insulin AUC significantly decreased in the octreotide-LAR group, whereas only a trend toward a reduction was observed in the placebo-treated group (Fig. 2) . Thus, when changes in insulin AUC were compared between the two groups, a significant difference was found (P ϭ 0.038).
HOMA significantly decreased and QUICKI significantly increased in both groups, whereas ISI(composite) significantly increased only in the octreotide-LAR-treated group (Fig. 3 ). There were no significant differences in the changes in insulin resistance indices after each treatment between the two groups, apart from a trend toward a greater increment in ISI(composite), with a borderline significance (P ϭ 0.059), after octreotide-LAR administration.
GH, IGF, IGFBPs, and ghrelin
No significant between-group differences in baseline GH, IGF, IGFBPs, or ghrelin levels were observed. GH, IGF-I, and total ghrelin levels significantly decreased, and IGFBP-1, IGFBP-2, and IGFBP-3 significantly increased in the group treated with octreotide-LAR, whereas no significant modifications occurred in the placebo group (Table 3) . However, compared with placebo, only changes in IGFBP-2, IGFBP-3, and total ghrelin were significantly higher after octreotide-LAR administration (P ϭ 0.042 for IGFBP-2; P ϭ 0.047 for IGFBP-3; P ϭ 0.002 for total ghrelin).
Clinical parameters, menstrual cycles, and ovulation
Because eight of the 11 PCOS patients who were hirsute at baseline were treated with octreotide-LAR and three were given placebo, the pretreatment hirsutism score was significantly higher in the former than in the latter (P ϭ 0.01). All women had acanthosis nigricans, and both groups had a similar score at baseline. After treatment, the hirsutism and acanthosis nigricans scores significantly decreased only in the octreotide-LAR group (Table 4 ). The greater effect of octreotide-LAR with respect to placebo was confirmed when the changes that occurred in these two parameters were compared between the two groups (P ϭ 0.004 for hirsutism score; P ϭ 0.008 for acanthosis nigricans score).
Menstrual cyclicity at baseline was similar in the two groups, and it significantly and similarly improved after treatments in both groups (Table 4) . Anovulation was present during the first posttreatment menstrual cycle in all women. Conversely, during the last treatment cycle, ovulation occurred in all patients treated with octreotide-LAR, but in only one of those given placebo (Table 4) . Overall ovulatory rates were therefore significantly higher during oct- reotide-LAR than placebo treatment (P Ͻ 0.001). The hormonal profile assessed in the first and last treatment cycles of each group is shown in Fig. 4 . Both groups had a similar hormonal profile at the first cycle, apart from FSH levels on d 28, which were significantly higher in the octreotide-LAR group than in the placebo group. However, significant differences appeared between the two groups at the last treatment cycle. In particular, P was significantly higher in the octreotide-LAR group than in the placebo group on both d 21 and 28 of the menstrual cycle. Moreover, the octreotide-LAR-treated group showed higher levels of LH and E 2 and lower levels of FSH than the placebo group on d 28. The overall profiles of LH, FSH, E 2 , and P did not significantly change during the first treatment cycle for either group. Conversely, significant increases in E 2 (P ϭ 0.049) and P (P ϭ 0.012) and a significant decrease in FSH (P ϭ 0.023) were observed only in the octreotide-LAR group in the last treatment cycle. No significant overall modifications occurred in the LH profile in either group. Compared with the effects of placebo, only changes in E 2 and P were persistently significantly higher after octreotide-LAR administration (P ϭ 0.044 for E 2 ; P ϭ 0.009 for P).
One woman in the octreotide-LAR group conceived spontaneously in the second cycle after discontinuing treatment and successfully completed an uneventful singleton gestation.
Discussion
This is the first report of the effect and safety features of long-term treatment with octreotide-LAR in dieting abdominally obese women with PCOS. We found that the addition of octreotide-LAR significantly amplified the effects of a low-calorie diet; fasting and glucose-stimulated insulin levels; insulin resistance; and androgen, GH, and IGF-I concentrations were reduced, whereas circulating IGFBP levels were increased by octreotide-LAR. This treatment also significantly improved hirsutism and acanthosis nigricans. The menstrual pattern appeared to improve in a similar manner in both groups; however, compared with the effect in placebo-treated women, octreotide-LAR demonstrated a particularly strong efficacy in improving the ovulatory rate. Conversely, octreotide-LAR administration did not additionally improve the positive effects on body composition and fat distribution of a low-calorie diet. This result partly confirms our previous reports (25, 36) showing that changes in body composition mainly depend on diet and that they are only marginally improved when insulin sensitivity and hyperandrogenemia are further corrected by the administration of insulin-sensitizing (36) and antiandrogenic (25) drugs in dieting obese PCOS women. Interestingly, octreotide-LAR administration was more effective than placebo in reducing fasting and glucose-stimulated insulin lev- els and in improving ISI (composite) and thus insulin resistance. This finding is consistent with the previously reported efficacy of octreotide-LAR to directly influence insulin secretion (9, 37) and thus with its potential role as an insulin-sensitizing agent. The ability of octreotide to decrease pancreatic insulin release in addition to improving peripheral insulin sensitivity may explain the marginal effect on glucose tolerance we observed in the octreotide-LAR-treated PCOS patients in the current study. Although previous studies reported the occurrence of some degree of glucose intolerance after treatment with octreotide, this effect may be dependent on the use of higher doses of octreotide (37) .
As expected, octreotide-LAR reduced circulating GH levels, and this can be explained by its well-known ability to inhibit pituitary GH secretion and GHRH hypothalamic release (38) . In contrast, the significant and selective decrease in circulating ghrelin, the most important endogenous GH secretagogue, may represent an additional mechanism to explain the inhibitory effect of octreotide-LAR on the GH/ IGF-I system, as reported in previous studies (39) . Octreotide-LAR also significantly increased IGFBP-1, IGFBP-2, and IGFBP-3, thus favoring a decrease in free IGF-I levels and, therefore, in IGF-I availability to the target tissues. We speculated that combined reduction of insulin and IGF-I levels may represent the key mechanism responsible for the decrement in androgen levels we found in PCOS patients treated with octreotide-LAR, because no direct effects of somatostatin or its analogs on ovarian steroidogenesis have been demonstrated to date (40) . Our data also indirectly support the concept that octreotide-LAR did not affect adrenal steroidogenesis, because no significant changes in cortisol and DHEA-S concentrations occurred during the study. Unexpectedly, we found that octreotide-LAR had no effect on LH levels, a finding that contradicts other clinical studies in PCOS women (12, 13, 15, 16, 18, 19) . However, previous studies examined integrated LH concentrations after frequent blood sampling (12, 13) or LH responsiveness to GnRH agonist (16), whereas we performed only single fasting LH measurements; this methodological approach may have limited our ability to assess variations in LH secretion. Furthermore, in contrast with all other published studies, in which normal weight or moderately obese PCOS women were examined, we mainly assessed frankly obese PCOS women with an abdominal phenotype, a condition characterized by lower and sometimes virtually normal LH levels (2) .
Octreotide-LAR also had evident clinical effects, because it significantly improved hirsutism and acanthosis nigricans, probably related to the efficacy of octreotide in reducing hyperandrogenemia and in improving insulin resistance and hyperinsulinemia. A novel feature of this study was the strong effect exerted by octreotide-LAR on the ovulatory status of PCOS women, which appeared to be relatively independent from changes in menstrual cyclicity. Our finding that menstrual cycle patterns improved similarly in both octreotide-LAR and placebo groups suggests that weight loss and energy restriction were probably the major factors responsible for this effect. The lack of an increase in P in the last menstrual cycle of the study, found in all but one woman in the placebo group, indicates that anovulation persisted in these subjects. Conversely, all women receiving octreotide-LAR ovulated at the end of treatment despite limited changes in serum gonadotropin levels. The presence of somatostatin receptors in human granulosa-luteal cells and human follicles makes it conceivable that octreotide-LAR affects the ovulatory process through a direct action at the ovarian level (11) . This process may particularly involve all mechanisms dependent on regulation of the insulin-IGF system, including IGFBP action. In particular, although the action of IGFBPs in the modulation of ovarian function, such as follicular growth, recruitment, and atresia, and hormone biosynthesis is not well known (5), it is likely that changes in their circulating concentrations and intraovarian functions are important to explain the good performance of octreotide-LAR to increase ovulation in abdominal obese PCOS.
Potential limitations of this study include the single-blind design, which is only partially compensated by the careful criteria of selection and randomization of the patients and by the fact that the investigator assessing the outcomes was blinded to treatment assignment. Therefore, additional, larger, double-blinded trials are needed to confirm the clinical relevance of our findings.
In conclusion, this study shows that long-term administration of octreotide-LAR had several benefits on the clinical, metabolic, and hormonal parameters of dieting abdominal obese PCOS women, and that it was able to restore ovulatory status in otherwise anovulatory patients. This treatment seems to be safe and well tolerated, thus providing the basis for a novel application of octreotide-LAR in the treatment of hormonal dysfunction and infertility in PCOS women.
